



# Amniotic Fluid Embolism

Click the next button to continue...



Copyright © 2024 Shelly Betancourt and Michelle Becher

All rights reserved. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the publisher, except in the case of brief quotations embodied in critical reviews and certain other noncommercial uses permitted by copyright law. For permission requests, write to the publisher at the address below.

Maternal 911 Education Systems, LLC  
475 West Center St.  
Ithaca, MI 48847  
[www.maternal911.com](http://www.maternal911.com)

Maternal 911 and Maternal 911 in Action contains information designed as an educational resource to aid practitioners in providing obstetric care and the use of this information is voluntary. This information should not be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. It is not intended to substitute for the independent professional judgement. Maternal 911 reviews the publication regularly, but may not reflect the most recent evidence.

Maternal 911 makes every effort to present accurate and reliable information. The Maternal 911 and Maternal 911 in Action are publications provided 'as is' without any warranty of accuracy, reliability or otherwise, either express or implied. Maternal 911 does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither co-founder nor any officers, directors, members, employees, participants or agents will be liable for any loss, damage or claim with respect to liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.


Data from completing the modules may be used in research and publications with privacy maintained.



**Course Description:**

Amniotic Fluid Embolism (AFE) is a high acuity, low occurring process that when recognized may be life-saving. The course will help by giving understanding of the disease and its management.

**Approximate Time to Complete:** 40 minutes



**The purpose of this module is to improve participant's understanding of amniotic fluid embolism.**

- Explain how amniotic fluid embolism can occur.
- Identify risks associated with amniotic fluid embolism.
- Recognize the signs and symptoms of amniotic fluid embolism so prompt health care delivery can be implemented.
- Initiate the initial steps of amniotic fluid embolism resuscitation with the application of equipment.
- Describe the medications used for resuscitation and how they may affect the mother and fetus.

- How to use the module
- Amniotic Fluid Embolism
  - AFE
  - Occurrence
  - Risk Factors
  - Etiology
- Symptoms and Clinical Presentation
  - Cardiogenic Shock
  - Respiratory Failure
  - Inflammation
  - Clinical Presentation
- Diagnosis and Management
  - Diagnosis
  - Management
  - Invasive Monitoring
  - Oxygen
  - Hemodynamics
  - Vasoactive Agents
  - IV Fluids
  - Blood Products
  - Delivery
  - Prognosis and Complications
- Summary
  - Summary
  - Course Completed Page



### Amniotic Fluid Embolism (AFE)

- *A rare, sporadic, unpredictable condition that can occur in pregnancy or immediately postpartum and may lead to cardiovascular collapse [1-3].*
  - *Also called anaphylactoid syndrome of pregnancy.*
  - *AFE is believed to be triggered by the abnormal release of trophoblasts or other material into the maternal circulation.*
  - *Other cells from the fetal compartment can cause the AFE, rather than only amniotic fluid as the name implies.*
- 
- First reported in 1926.
  - Not widely recognized until 1941.
  - In 1941, autopsies from a series of eight women who died from sudden shock during labor reported squamous cells and mucin of fetal origin in the maternal pulmonary vasculature [4,5].
  - These same fetal squamous cells have been described in the vascular beds of maternal kidneys, liver, spleen, pancreas and brain [6].





- The condition typically presents with hemodynamic and respiratory compromise in addition to disseminated intravascular coagulopathy (DIC).
- The incidence is between 1-12 cases per 100,000.
- However, due to the lack of international consensus regarding diagnostic criteria, estimates of both incidence and mortality rates associated with AFE vary widely [56].

AFE appears to involve complex events triggered in certain women by entrance into the maternal circulation of material from the fetal compartment, resulting in an abnormal proinflammatory mediator system activation similar to the systemic inflammatory responses syndrome (SIRS) [56].


Several factors have been associated with AFE [7,12,13], including, but not limited to:

- Precipitous or tumultuous labor
- Advanced maternal age
- Cesarean and instrumental delivery
- Placenta previa, placental abruption, placenta accreta, percreta, or increta
- Grand multiparity ( $\geq 5$  live births or stillbirths)
- Cervical lacerations
- Fetal distress
- Eclampsia
- Medical induction of labor
- Uterine rupture
- Polyhydramnios
- Miscarriage or abortion
- Amniocentesis

AFE is best considered unpreventable and unpredictable.



- The pathogenesis of AFE is thought to involve the amniotic fluid or other fetal compartment cells entering the maternal circulation through endocervical veins, the placental insertion site or a site of uterine trauma [14].
- Once the amniotic fluid or other fetal compartment cells reaches the maternal circulation, it can precipitate cardiogenic shock, respiratory failure and most likely, an inflammatory and anaphylactoid response.



**Example of amniotic fluid embolism**

Yale Rosen, CC BY-SA 2.0 <<https://creativecommons.org/licenses/by-sa/2.0/>>, via Wikimedia Commons

Etiology



**Figure A: Proposed Pathophysiology of Amniotic Fluid Embolism (AFE)**



Click each box for more information.





Figure A





- Amniotic fluid has been shown to cause occlusion and vasospasm of the maternal pulmonary vasculature with animal studies, resulting in rapid development of pulmonary hypertension, acute cor pulmonale and systemic hypotension [15-17].
  - In women with AFE, invasive hemodynamic studies seem to contradict these animal studies [18,19].
  - When elevated pulmonary arterial pressure, elevated pulmonary capillary wedge pressure, decreased cardiac output and decreased cardiac index are combined, it suggests the principal hemodynamic alteration in humans is left ventricular failure, rather than pulmonary hypertension and right ventricular failure.

- To reconcile the human and animal observations, a biphasic pattern of cardiogenic shock in AFE has been proposed [2,15,19].
- Initial acute pulmonary hypertension and right ventricular failure (usually lasting 15-30 minutes), according to the hypothesis, is followed by left ventricular dysfunction [20,21].
- Studies utilizing transesophageal echocardiography to non-invasively measure the hemodynamic parameters early during AFE, demonstrate vasospasm of the pulmonary vasculature, elevated pulmonary arterial pressure and right ventricular failure, thus supporting the biphasic hypothesis [20,21].
- The late phase of left ventricular dysfunction is poorly understood.



**The mechanism may involve:**

- Hypoxic injury to the left ventricle
- Release of maternal inflammatory mediators
- Direct depressant effect of amniotic fluid on the myocardium



*Mouse over the heart to see what the mechanism may involve.*



- Among patients with AFE, hypoxemia is the most common manifestation of the resultant respiratory failure.
- Hypoventilation can also occur.
- The primary cause of hypoxemia involves severe ventilation/perfusion (V/Q) mismatching.

**Factors contributing to  
the V/Q mismatch [2] :**

- Acute pulmonary hypertension during the first phase of cardiogenic shock
- Cardiogenic pulmonary edema during the second phase

**Other contributors  
may include [8, 22] :**

- Bronchospasm (about 15% of patients)
- Noncardiogenic pulmonary edema

- In 70% of patients who survive the first several hours, noncardiogenic pulmonary edema occurs [22].
- It generally develops as left ventricular dysfunction improves.
- Damage to the endothelial-alveolar membrane and capillary leak syndrome likely to lead to high protein concentration in edematous fluid and the presence of amniotic debris in sputum and alveolar spaces.
- Widespread damage to the alveolar-capillary membrane causes non-cardiogenic edema to occur in AFE; it usually does not produce the clinical pattern typical of acute respiratory distress syndrome (ARDS).
- Women who survive the first few hours of AFE usually recover quite rapidly, whereas the course of ARDS tends to be protracted.



- Obstruction of the pulmonary vasculature seems unlikely to be the lone cause of AFE, since there is often a lag of many hours between the entry of amniotic fluid into the the maternal circulation and onset of symptoms and signs of AFE.
- Propositions have brought up how the lag may reflect evolution of AFE as an immunologic response or inflammatory reaction to the amniotic fluid.
- Support is evident by reports of decreased complement and increased inflammatory markers in some patients with AFE, including elevated serum trypsin levels and pulmonary mast cell activity [23-28].
- It is hypothesized that AFE is caused by a breach in the normal physiologic barrier between the mother and fetus.
- The clinical manifestations and the severity may be related to the degree of immunologic stimulation or the balance of arachidonic acid metabolites such as leukotrienes in the amniotic fluid [29,30].

- The symptoms and signs associated with AFE have a typical onset during labor and delivery, or immediately postpartum [2].
- In rare instances, it has been reported following first or second trimester abortion, amniocentesis, or abdominal/uterine trauma, and as late as 48 hours after cesarean delivery or post partum, [8, 31-35].
- Most women present with rapid cardiorespiratory collapse [10].
- Preceding the onset of dyspnea and hypotension may be nonspecific symptoms such as chills, nausea, vomiting and agitation [8,10].
- A less severe presentation of AFE, may present with only some of the major symptoms and signs [15,36,37].
  - These patients with partial AFE generally present with sudden onset of milder dyspnea and hypotension.
  - In this situation, the clinical course tends to be abbreviated and the prognosis much better compared to those who have the full syndrome.



The major clinical findings are the abrupt and fulminant onset of:



Click the terms in blue to learn more.

Hypotension due to cardiogenic shock

DIC

Hypoxemia and respiratory failure

Coma or seizures

- A prominent feature of AFE is hypotension due to cardiogenic shock.
- When AFE occurs in women, approximately 85% die from cardiogenic shock or its complications [10].
- The management of cardiogenic shock may be complicated by cardiac dysrhythmias.
- The cardiac dysrhythmia could include pulseless electrical activity, bradycardia, ventricular fibrillation, and asystole [8].
- Management of the cardiogenic shock and dysrhythmias is supportive.



The major clinical findings are the abrupt and fulminant onset of:



Click the terms in blue to learn more.

Hypotension due to cardiogenic shock

DIC

Hypoxemia and respiratory failure

Coma or seizures

- A common early finding of AFE is profound hypoxemia.
- Hypoxemia is most commonly detected by pulse oximetry, but clinical findings include confusion, agitation, somnolence, dyspnea, tachycardia, tachypnea, cyanosis, and acidemia.
- Evidence may include crackles and radiographic air space disease when cardiogenic or noncardiogenic pulmonary edema is present.
- Wheezing is occasionally detected.
- Approximately 50% of the deaths are caused by profound hypoxemia and occur within the first hour of the AFE.
- Prolonged hypoxemia may lead to permanent, severe neurologic impairment or maternal brain death [8].



The major clinical findings are the abrupt and fulminant onset of:



Click the terms in blue to learn more.

Hypotension due to cardiogenic shock

DIC

Hypoxemia and respiratory failure

Coma or seizures

- Nearly 80% of women with AFE develop DIC [1,2,8].
- DIC can begin 10-30 minutes after the onset of cardiopulmonary signs and symptoms. However, DIC may also be delayed by as many as four hours [2,38-41].
- The most common manifestations of DIC are prolonged bleeding from sites of invasive interventions, such as intravenous (IV) sites, and bruising.
- However, in some cases, major hemorrhage may be the clinical manifestation.
- When hemorrhage occurs, it can delay the diagnosis of AFE since an exhaustive search for structural causes of hemorrhage will likely occur [42].



The major clinical findings are the abrupt and fulminant onset of:



Click the terms in blue to learn more.

Hypotension due to cardiogenic shock

DIC

Hypoxemia and respiratory failure

Coma or seizures



Encephalopathy (which may progress to a coma) associated with AFE is thought to be secondary to hypoxia and includes a spectrum of symptoms ranging from altered mental state to seizures. Tonic-clonic seizures are seen in 10-50% of patients [55].



**AFE is diagnosed based on the collection of clinical findings, rather than isolated signs and symptoms.**

- AFE should be suspected whenever shock and/or respiratory compromise develops during labor or immediately postpartum.
- Other causes of sudden intrapartum or postpartum cardiorespiratory failure must be excluded.
- Amniotic fluid debris is common in maternal circulation without AFE, so finding the amniotic fluid debris alone should not be considered diagnostic [43].

- There is no specific treatment for AFE.
- The therapeutic goal is to correct hypoxemia and hypotension so that ischemic consequences (i.e. hypoxic brain injury, acute kidney injury) are prevented in the mother and adequate oxygen delivery occurs to the fetus.



- Monitoring of maternal oxyhemoglobin saturation, heart rate and rhythm, and respiratory rate should be immediately initiated in all patients with suspected AFE.
- It is important to monitor the blood pressure non-invasively at frequent intervals until continuous blood pressure monitoring is established.
- Continuous monitoring of the fetal heart rate is recommended.



High quality cardiopulmonary resuscitation in pregnancy is needed.

Components [56]:

- rapid chest compressions (100 times per minute)
- perform hard compressions, achieving a depth of at least 2 inches
- assure adequate chest recoil between compressions
- minimize interruptions of chest compressions
- avoid prolonged pulse checks (5-10 seconds at the most)
- switch provider of compressions every 2 minutes to avoid fatigue
- lateral displacement of uterus during resuscitation.



## Invasive Monitoring

- As clinical suspicion for AFE arises, plans should be made for both an arterial and a central venous catheter to be inserted.
- Additional management measures should not be delayed for catheter insertion as these procedures can be time consuming.
- An arterial catheter can be used to continuously monitor blood pressure.
- It also provides access to arterial blood for frequent measurement of arterial blood gases.

Slide 1 of 3



## Invasive Monitoring

**The central venous catheter can be used to:**

- Infuse IV fluids
- Infuse medications (i.e. vasopressors, inotropics, etc.)
- Infuse blood products
- Draw venous blood
- The central line can be used for limited hemodynamic monitoring by measuring the central venous pressure and the central venous oxyhemoglobin saturation.

## Invasive Monitoring

- Hemodynamic monitoring via a pulmonary arterial catheter should not be performed routinely.



## Supplemental Oxygen

Click each of the buttons to reveal more information about supplemental oxygen for AFE.

**Supplemental oxygen**

**Factors that impair oxygen delivery to the fetus**

**Maternal and Fetal Oxygen Status**

**Compensatory Factors**

## ✕ Supplemental Oxygen


- Supplemental oxygen should be provided to all patients.
- Reaching a maternal oxygen tension ( $\text{PaO}_2$ ) above 65 mmHg is a reasonable goal.
- To reach this goal, it often requires high flow rates of supplemental oxygen by facemask or invasive mechanical ventilation.
- If mechanical ventilation is required, the following parameters can be adjusted:
  - Increasing the fraction of inspired oxygen
  - Increasing the positive end-expiratory pressure
  - Prolonging or inverting the inspiratory to expiratory ratio.
  - Due to the associated high risk of aspiration, non-invasive positive pressure ventilation should be avoided during pregnancy.





## Factors that impair oxygen delivery to the fetus

- Factors impairing oxygen delivery to the fetus such as anemia or diminished cardiac output should be corrected.
- This may involve red blood cell transfusions and inotropic agents.
- If the woman has delivered, these factors (i.e. anemia, diminished cardiac output) should be corrected if there is evidence of persistent hypoperfusion despite optimization of the PaO<sub>2</sub>.
- Common signs of hypoperfusion include:
  - Cool, vasoconstricted skin due to redirection of blood flow to core organs (however, warm flushed skin may be present early on in phases of sepsis)
  - Obtundation or restlessness
  - Oliguria or anuria
  - Lactic acidosis






## Maternal and Fetal Oxygen Status

- If the patient is not delivered, the maternal oxygen status dictates fetal oxygen status.
- The delivery of fetal oxygen is directly related to umbilical vein oxygen tension, umbilical vein oxyhemoglobin saturation, fetal hemoglobin concentration, and maternal cardiac output.
- Healthy pregnant women have increased fetal hemoglobin concentration and maternal cardiac output. These compensate for low umbilical vein oxygen tension, so as to maintain sufficient fetal oxygen delivery.






Peter Southwood [CC0]: [https://commons.wikimedia.org/wiki/File:Oxygen-Haemoglobin\\_dissociation\\_curves.svg](https://commons.wikimedia.org/wiki/File:Oxygen-Haemoglobin_dissociation_curves.svg)

- For women who are intravascularly normovolemic or hypervolemic, a vasopressor is the preferred initial therapy.
- If the intravascular volume is unknown, it is recommended to begin empiric therapy with a vasopressor.
  - This recommendation is based on the observations showing hypotension in AFE is almost always due to cardiogenic shock and coexisting intravascular hypovolemia is rare.

- When vasopressor therapy is warranted, norepinephrine and dopamine are the typical drugs of first choice.
- The inotrope, dobutamine, may be added and would likely be beneficial since it increases the low cardiac output and decreases the high afterload that is characteristic of cardiogenic shock.
- However, until the vasopressors have improved blood pressure, dobutamine should not be used.
- Dobutamine, when used alone, tends to reduce blood pressure by causing a drop in the systemic vascular resistance that is out of proportion to the increase in cardiac output.





# Vasoactive Drugs

Click on the buttons below to reveal more about vasoactive drugs.

**Vasopressors  
and  
Hypotension**

**Untreated  
Shock**

**Adverse  
Outcomes of  
Vasopressors**

**What a  
vasopressor  
does for blood  
pressure**

**What  
an inotrope  
for blood  
pressure**

**Summary**



## Vasopressors and Hypotension

Vasopressors are used to treat hypotension in AFE even though they may diminish uteroplacental perfusion pressure.

**Vasopressors and Hypotension**


**Untreated Shock**

**Adverse Outcomes of Vasopressors**

**What a vasopressor does for blood pressure**

**What an inotrope for blood pressure**

**Summary**



## Untreated Shock

The rationale is that untreated shock diminishes uteroplacental perfusion pressure and has numerous additional potential adverse consequences.

**Vasopressors  
and  
Hypotension**

**Untreated  
Shock**

**Adverse  
Outcomes of  
Vasopressors**

**What a  
vasopressor  
does for blood  
pressure**

**What  
an inotrope  
for blood  
pressure**

**Summary**



## Adverse Outcomes of Vasopressors

- Decreasing fetal oxygen delivery
- Increasing the mother's risk of ischemic complications
- Acute kidney injury
- Hypoxic brain injury
- Increasing mother's risk of death

**Vasopressors and Hypotension**

**Untreated Shock**

**Adverse Outcomes of Vasopressors**

**What a vasopressor does for blood pressure**

**What an inotrope for blood pressure**

**Summary**



## What a vasopressor does for blood pressure

- Stimulates smooth muscle contraction of the capillaries and arteries
- This leads to vasoconstriction
- A rise in mean blood pressure
- Improved tissue perfusion and oxygenation

Vasopressors and Hypotension

Untreated Shock

Adverse Outcomes of Vasopressors

What a vasopressor does for blood pressure

What an inotrope for blood pressure

Summary





## What an inotrope does for blood pressure

- Increase the force of contraction of myocardial muscle
- This leads to positive inotropism
- Rise in mean blood pressure
- Improved tissue perfusion and oxygenation

Vasopressors and Hypotension

Untreated Shock

Adverse Outcomes of Vasopressors

What a vasopressor does for blood pressure

What an inotrope does for blood pressure

Summary





## Vasoactive Drugs

### Vasopressors



Stimulates smooth muscle contraction of the capillaries & arteries



Vasoconstriction

### Inotropes



Increase the force of contraction of myocardial muscle



Positive inotropism

- Vasopressors are used to treat hypotension in AFE even though they may diminish uteroplacental perfusion pressure.
- The rationale is that untreated shock diminishes uteroplacental perfusion pressure and has numerous additional potential adverse consequences.

### These include:


- Decreasing fetal oxygen delivery
- Increasing the mother's risk of ischemic complications
- Acute kidney injury
- Hypoxic brain injury
- Increasing mother's risk of death



- Pulmonary edema is common in AFE so a cautious approach is necessary whenever a trial of IV fluid is selected.
- When IV fluid is given, it is necessary to be administered in small boluses with recurrent assessment being required.
- The IV fluids should be discontinued when the intravascular volume has been replenished.
- The IV fluids should be promptly discontinued when new or worsening pulmonary edema occurs.
- When the pulmonary edema worsens with a trial of IV fluids, these women should be regarded as having uncertain intravascular volume and may be better managed with vasoactive agents.

The development of DIC is common in the setting of AFE. If DIC is noted, massive transfusion protocols should be administered as supportive care.

Some studies have investigated the use of recombinant factor VIIa in the setting of AFE; however, the use of this product has unclear benefit and some studies have demonstrated worse outcomes.



# AFE Intrapartum

- When AFE presents intrapartum, the need for immediate delivery must be determined.
- Need for immediate delivery is determined on an individual basis; however, factors supporting delivery include:

Click the buttons below to reveal the factors



Factor 1

Factor 2

Factor 3

Factor 4

Factor 5

Delivery



## Non-reassuring fetal heart rate tracing

Factor 1

Factor 2

Factor 3

Factor 4

Factor 5

Delivery



Rapid and progressive deterioration of the mother's condition

Factor 1

Factor 2

Factor 3

Factor 4

Factor 5

Delivery



The opinion that delivery of the fetus may facilitate maternal resuscitative efforts

Factor 1

Factor 2

Factor 3

Factor 4

Factor 5

Delivery



Otherwise, an emergency cesarean delivery is indicated.

Factor 1

Factor 2

Factor 3

Factor 4

Factor 5

Delivery



Otherwise, an emergency cesarean delivery is indicated.

Factor 1

Factor 2

Factor 3

Factor 4

Factor 5

Delivery

- Consideration for peri-mortem cesarean is warranted when shock and cardiopulmonary resuscitative efforts fail to restore maternal circulation.
- Because brain damage begins at 5 minutes of anoxia, the procedure should be initiated at 4 minutes to deliver the healthiest fetus.
- If a mother has a resuscitatable cause of death, then her life may be saved as well by a prompt and timely cesarean delivery during CPR.
- Sadly, the clinicians are too often paralyzed by the horror of the maternal cardiac arrest and instinctively CPR is performed too long before turning to the perimortem delivery.
- This quick procedure may actually improve the situation for the mother and can potentially save the infant's life [45].



- There is significant risk of major maternal morbidity or death when a cesarean is performed in the presence of coagulopathy.
- Blood, fresh frozen plasma, platelets, and cryoprecipitate should be available and administered if there is any evidence of impaired coagulation:
  - Persistent bleeding without clotting from the incision
  - Needle site bleeding

Case reports have described novel interventions that have been successfully used in patients with AFE:

- A right ventricular device and inhaled nitric oxide have been used in patients with right ventricular failure and pulmonary hypertension [46,47].
- In patients with severe left ventricular failure and hypoxemia, the following have been utilized: cardiopulmonary bypass, intraaortic balloon pump counterpulsation and extracorporeal membrane oxygenation (ECMO) [21,48].
- The use of recombinant human factor VIIa (rVIIa) may be utilized when severe coagulopathy and bleeding, especially in those undergoing surgery to control postpartum hemorrhage. [47,49].
- Unfortunately, rVIIa use in AFE may be associated with thrombotic morbidity and mortality (i.e. stroke and pulmonary embolism).

**Maternal**

**Neonatal**



*Click the blue buttons to learn more.*

- Neonatal outcomes are also poor.
  - The mortality rate is estimated to be between 20 and 60% [8,9].
  - Only 50% of survivors are neurologically intact.
- When the mother sustains an an AFE-induced cardiac arrest, overall neonatal outcomes are improved with prompt delivery of the fetus [54].



Case reports have described novel interventions that have been successfully used in patients with AFE:

- A right ventricular device and inhaled nitric oxide have been used in patients with right ventricular failure and pulmonary hypertension [46,47].
- In patients with severe left ventricular failure and hypoxemia, the following have been utilized: cardiopulmonary bypass, intraaortic balloon pump counterpulsation and extracorporeal membrane oxygenation (ECMO) [21,48].
- The use of recombinant human factor VIIa (rVIIa) may be utilized when severe coagulopathy and bleeding, especially in those undergoing surgery to control postpartum hemorrhage. [47,49].
- Unfortunately, rVIIa use in AFE may be associated with thrombotic morbidity and mortality (i.e. stroke and pulmonary embolism).

Maternal

Neonatal



*Click the blue buttons to learn more.*

- Maternal mortality rate due to AFE has been reported between 10 to 90% [1,7,8,50-53], although more recent data suggest overall mortality rates may be closer to 20 percent [7,11,12].
- Even those surviving AFE generally have a poor outcome with as many as 85% suffering significant neurologic injury due to cerebral hypoxia [2,8].
- AFE is one of the leading causes of maternal mortality and is reported to cause ten percent of all maternal deaths in developed countries [53].



*Click the symbol for more information.*

Medications



An article in Obstetrics & Gynecology titled “[Use of Atropine, Ondansetron, and Ketorolac in Suspected Amniotic Fluid Embolism](#)” by Pacheco et al. (2025) cautions against the use of these medications, emphasizing that standard supportive care including:

- rapid recognition
- high-quality resuscitation
- hemodynamic support
- aggressive management of coagulopathy

These four listed remain the cornerstone of treatment for AFE.

After reviewing the available literature, currently limited to case reports, the authors conclude that there is insufficient evidence to support the safety and efficacy of these medications in treating AFE. The paper also outlines potential risks, including worsening coagulopathy, kidney injury, and cardiac complications.

SMFM [57] has a checklist with further information to delineate what needs to be modified for each facility.

Here is a sample:



*Click on the picture to download a copy of the checklist.*



**Amniotic Fluid Embolism Checklist, Initial Management**  
 Note: the checklist should be modified to fit facility specific circumstances

**Manage circulatory collapse**

- CAB's: manage circulation, airway, and breathing
- Designate a timekeeper to call out times at 1 min intervals
- If no pulse, start CPR
  - Manually displace uterus or lateral tilt
  - Use backboard
- Move to operating room only if this can be accomplished in 2 minutes or less
- If no pulse by 4min, START peri-mortem cesarean delivery (resuscitative hysterotomy)
  - Splash prep only, do not wait for antibiotics
  - Goal is to improve chances of resuscitation

**Anticipate uterine atony, DIC, hemorrhage**

- Oxytocin prophylaxis plus other uterotonics as needed
- Consider intraosseous line if needed for large-bore IV access
- Initiate massive transfusion protocol
  - B Cryoprecipitate preferred over FFP to reduce volume overload
  - Consider thromboelastometry, if available
- Tranexamic acid (q IV over 10 min) if DIC or hemorrhage occurs

**Manage Pulmonary Hypertension and Right Ventricular Failure (anesthesiology, Critical Care, or Cardiology)**

- Consider echocardiography (thoracic or esophageal)
- Avoid fluid overload (i.e. 500mL boluses and reassess)
- Vasopressor if needed: norepinephrine 0.05-3.3mg/kg/min
- Inotropes if needed:
  - Dobutamine 2.5-5.0mg/kg/min or
  - Milrinone 0.25-0.75mg/kg/min
- Pulmonary vasodilator if needed to unload right ventricle
  - Inhaled nitric oxide 5-40ppm or
  - Inhaled epoprostanol 10-50ng/kg/min or
  - IV epoprostanol 1-2ng/kg/min (via central line) or
  - Sildenafil 20mg orally (if awake/alert)
- Consider ECMO if prolonged CPR or refractory right heart failure
- Wean FIO<sub>2</sub> to maintain O<sub>2</sub> Saturation 94% to 98%

**Post-event debriefing (entire team)**

- Identify opportunities for improvement including any need for revisions to checklist
- Discuss family and staff support needs
- Report case to Amniotic Fluid Embolism Registry

© Maternal 911 Education Systems, LLC | 475 West Center Street | Ithaca MI 48847 | maternal911.com

## **Amniotic Fluid Embolism Checklist, Initial Management**

Note: the checklist should be modified to fit facility specific circumstances

### Manage circulatory collapse

- CAB's: manage circulation, airway, and breathing
- Designate a timekeeper to call out times at 1 min intervals
- If no pulse, start CPR
  - Manually displace uterus or lateral tilt
  - Use backboard
- Move to operating room only if this can be accomplished in 2 minutes or less
- If no pulse by 4min, START peri-mortem cesarean delivery (resuscitative hysterotomy)
  - Splash prep only, do not wait for antibiotics
  - Goal is to improve chances of resuscitation

### Anticipate uterine atony, DIC, hemorrhage

- Oxytocin prophylaxis plus other uterotonics as needed
- Consider intraosseous line if needed for large-bore IV access
- Initiate massive transfusion protocol
  - B Cryoprecipitate preferred over FFP to reduce volume overload
  - Consider thromboelastometry, if available
- Tranexamic acid (1g IV over 10 min) if DIC or hemorrhage occurs

### Manage Pulmonary Hypertension and Right Ventricular Failure (anesthesiology, Critical Care, or Cardiology)

- Consider echocardiography (thoracic or esophageal)
- Avoid fluid overload (i.e. 500mL boluses and reassess)
- Vasopressor if needed: norepinephrine 0.05-3.3mg/kg/min
- Inotropes if needed:
  - Dobutamine 2.5-5.0mg/kg/min or
  - Milrinone 0.25-0.75mg/kg/min
- Pulmonary vasodilator if needed to unload right ventricle
  - Inhaled nitric oxide 5-40ppm or
  - Inhaled epoprostanol 10-50ng/kg/min or
  - IV epoprostanol 1-2ng/kg/min (via central line) or
  - Sildenafil 20mg orally (if awake/alert)
- Consider ECMO if prolonged CPR or refractory right heart failure
- Wean FiO<sub>2</sub> to maintain O<sub>2</sub> Saturation 94% to 98%

### Post-event debriefing (entire team)

- Identify opportunities for improvement including any need for revisions to checklist
- Discuss family and staff support needs
- Report case to Amniotic Fluid Embolism Registry



- AFE is a catastrophic condition that occurs during pregnancy or shortly after delivery.
- AFE is characterized by abrupt and fulminant onset of hypotension due to cardiogenic shock, hypoxemia, respiratory failure, and DIC.
- AFE is unpredictable, unpreventable, and rare (occurring once in every 8,000 to 80,000 deliveries).
- AFE is a clinical diagnosis that is based upon the constellation of clinical findings.
- Clinicians should suspect AFE whenever shock or respiratory compromise develops during labor and delivery, or immediately postpartum.
- Other causes of sudden intrapartum or postpartum cardiorespiratory failure must be excluded.




*Click each box to review the course.*





- However, the goal is to expeditiously correct hypoxemia and hypotension so that ischemic consequences such as hypoxic brain injury, acute kidney disease, and myocardial injury are avoided in the mother and adequate oxygen is delivered to the fetus.
- This may require mechanical ventilation, vasopressors, inotropes, intravenous fluids, and blood products.
- Maternal mortality due to AFE remains high, although less than in previous years.
- This most likely reflects early recognition of the syndrome and appropriate aggressive therapy.
- Unfortunately, those who do survive generally have a poor outcome, most often caused by neurologic injury due to cerebral hypoxemia.
- Neonatal outcomes are also poor, although they improve with early delivery.





# Congratulations!

You have successfully completed this module.

*Click on the above 'X' to take the post-test for this course.  
If you do not attain a passing score after two attempts at the post-test the entire program must be repurchased.*

1. Gilmore DA, Wakim J, Secrest J, Rawson R. Anaphylactoid syndrome of pregnancy: a review of the literature with latest management and outcome data. *AANA J* 2003; 71:120.
2. Gist RS, Stafford IP, Leibowitz AB, Beilin Y. Amniotic fluid embolism. *Anesth Analg* 2009; 108:1599.
3. Clark SL. Amniotic fluid embolism. *Obstet Gynecol* 2014; 123:337.
4. Meyer, JR. Embolia pulmonar amnio caseosa. *Brasil Medico* 1926; 2:301.
5. Steiner PE, Lushbaugh CC. Landmark article, Oct. 1941: Maternal pulmonary embolism by amniotic fluid as a cause of obstetric shock and unexpected deaths in obstetrics. By Paul E. Steiner and C. C. Lushbaugh. *JAMA* 1986; 255:2187.
6. Liban E, Raz S. A clinicopathologic study of fourteen cases of amniotic fluid embolism. *Am J Clin Pathol* 1969; 51:477.
7. Abenhaim HA, Azoulay L, Kramer MS, Leduc L. Incidence and risk factors of amniotic fluid embolisms: a population-based study on 3 million births in the United States. *Am J Obstet Gynecol* 2008; 199:49.e1.
8. Clark SL, Hankins GD, Dudley DA, et al. Amniotic fluid embolism: analysis of the national registry. *Am J Obstet Gynecol* 1995; 172:1158.
9. Tuffnell DJ. United kingdom amniotic fluid embolism register. *BJOG* 2005; 112:1625.
10. Morgan M. Amniotic fluid embolism. *Anaesthesia* 1979; 34:20.
11. Kramer MS, Rouleau J, Baskett TF, et al. Amniotic-fluid embolism and medical induction of labour: a retrospective, population-based cohort study. *Lancet* 2006; 368:1444.
12. Knight M, Tuffnell D, Brocklehurst P, et al. Incidence and risk factors for amniotic-fluid embolism. *Obstet Gynecol* 2010; 115:910.
13. Turner LA, Kramer MS, Liu S, Maternal Mortality and Morbidity Study Group of the Canadian Perinatal Surveillance System. Cause-specific mortality during and after pregnancy and the definition of maternal death. *Chronic Dis Can* 2002; 23:31.
14. Courtney LD. Amniotic fluid embolism. *Obstet Gynecol Surv* 1974; 29:169
15. Clark SL. New concepts of amniotic fluid embolism: a review. *Obstet Gynecol Surv* 1990; 45:360.

16. Attwood HD, Downing ES. Experimental amniotic fluid and meconium embolism. *Surg Gynecol Obstet* 1965; 120:255.
17. Reis RL, Pierce WS, Behrendt DM. Hemodynamic effects of amniotic fluid embolism. *Surg Gynecol Obstet* 1969; 129:45.
18. Clark SL, Cotton DB, Gonik B, et al. Central hemodynamic alterations in amniotic fluid embolism. *Am J Obstet Gynecol* 1988; 158:1124.
19. Clark SL, Montz FJ, Phelan JP. Hemodynamic alterations associated with amniotic fluid embolism: a reappraisal. *Am J Obstet Gynecol* 1985; 151:617.
20. Shechtman M, Ziser A, Markovits R, Rozenberg B. Amniotic fluid embolism: early findings of transesophageal echocardiography. *Anesth Analg* 1999; 89:1456.
21. Stanten RD, Iverson LI, Daugharty TM, et al. Amniotic fluid embolism causing catastrophic pulmonary vasoconstriction: diagnosis by transesophageal echocardiogram and treatment by cardiopulmonary bypass. *Obstet Gynecol* 2003; 102:496.
22. Price TM, Baker VV, Cefalo RC. Amniotic fluid embolism. Three case reports with a review of the literature. *Obstet Gynecol Surv* 1985; 40:462.
23. Nishio H, Matsui K, Miyazaki T, et al. A fatal case of amniotic fluid embolism with elevation of serum mast cell tryptase. *Forensic Sci Int* 2002; 126:53.
24. Farrar SC, Gherman RB. Serum tryptase analysis in a woman with amniotic fluid embolism. A case report. *J Reprod Med* 2001; 46:926.
25. Benson MD, Kobayashi H, Silver RK, et al. Immunologic studies in presumed amniotic fluid embolism. *Obstet Gynecol* 2001; 97:510.
26. Fineschi V, Gambassi R, Gherardi M, Turillazzi E. The diagnosis of amniotic fluid embolism: an immunohistochemical study for the quantification of pulmonary mast cell tryptase. *Int J Legal Med* 1998; 111:238.
27. Benson MD. A hypothesis regarding complement activation and amniotic fluid embolism. *Med Hypotheses* 2007; 68:1019.
28. Benson MD. Current concepts of immunology and diagnosis in amniotic fluid embolism. *Clin Dev Immunol* 2012; 2012:946576.
29. Azegami M, Mori N. Amniotic fluid embolism and leukotrienes. *Am J Obstet Gynecol* 1986; 155:1119.

30. Benson MD. Nonfatal amniotic fluid embolism. Three possible cases and a new clinical definition. *Arch Fam Med* 1993; 2:989.
31. Lawson HW, Atrash HK, Franks AL. Fatal pulmonary embolism during legal induced abortion in the United States from 1972 to 1985. *Am J Obstet Gynecol* 1990; 162:986.
32. Hasaart TH, Essed GG. Amniotic fluid embolism after transabdominal amniocentesis. *Eur J Obstet Gynecol Reprod Biol* 1983; 16:25.
33. Mainprize TC, Maltby JR. Amniotic fluid embolism: a report of four probable cases. *Can Anaesth Soc J* 1986; 33:382.
34. Ellingsen CL, Eggebø TM, Lexow K. Amniotic fluid embolism after blunt abdominal trauma. *Resuscitation* 2007; 75:180.
35. Rainio J, Penttilä A. Amniotic fluid embolism as cause of death in a car accident-- a case report. *Forensic Sci Int* 2003; 137:231.
36. Masson RG, Ruggieri J, Siddiqui MM. Amniotic fluid embolism: definitive diagnosis in a survivor. *Am Rev Respir Dis* 1979; 120:187.
37. Wasser WG, Tessler S, Kamath CP, Sackin AJ. Nonfatal amniotic fluid embolism: a case report of post-partum respiratory distress with histopathologic studies. *Mt Sinai J Med* 1979; 46:388.
38. Peterson EP, Taylor HB. Amniotic fluid embolism. An analysis of 40 cases. *Obstet Gynecol* 1970; 35:787.
39. Beller FK. Disseminated intravascular coagulation and consumption coagulopathy in obstetrics. *Obstet Gynecol Annu* 1974; 3:267.
40. Bastien JL, Graves JR, Bailey S. Atypical presentation of amniotic fluid embolism. *Anesth Analg* 1998; 87:124.
41. Malhotra P, Agarwal R, Awasthi A, et al. Delayed presentation of amniotic fluid embolism: lessons from a case diagnosed at autopsy. *Respirology* 2007; 12:148.
42. Davies S. Amniotic fluid embolism and isolated disseminated intravascular coagulation. *Can J Anaesth* 1999; 46:456.
43. Lee W, Ginsburg KA, Cotton DB, Kaufman RH. Squamous and trophoblastic cells in the maternal pulmonary circulation identified by invasive hemodynamic monitoring during the peripartum period. *Am J Obstet Gynecol* 1986; 155:999.

44. Wulf KH, Kunzel W, Lehman V. Clinical aspects of placental gas exchange. In: Respiratory gas exchange and blood flow in the placenta, Longo LD, Bartels H (Eds), United States Public Health Service, Bethesda, MD 1972. p.505.
45. Katz, Vern L, MD; Perimortem Cesarean Delivery: Its Role in Maternal Mortality; Seminars in Perinatology, Volume 36, Issue 1, February 2012, Pages 68–72
46. McDonnell NJ, Chan BO, Frengley RW. Rapid reversal of critical haemodynamic compromise with nitric oxide in a parturient with amniotic fluid embolism. *Int J Obstet Anesth* 2007; 16:269.
47. Nagarsheth NP, Pinney S, Bassily-Marcus A, et al. Successful placement of a right ventricular assist device for treatment of a presumed amniotic fluid embolism. *Anesth Analg* 2008; 107:962.
48. Hsieh YY, Chang CC, Li PC, et al. Successful application of extracorporeal membrane oxygenation and intra-aortic balloon counterpulsation as lifesaving therapy for a patient with amniotic fluid embolism. *Am J Obstet Gynecol* 2000; 183:496.
49. Leighton BL, Wall MH, Lockhart EM, et al. Use of recombinant factor VIIa in patients with amniotic fluid embolism: a systematic review of case reports. *Anesthesiology* 2011; 115:1201.\
50. Gilbert WM, Danielsen B. Amniotic fluid embolism: decreased mortality in a population-based study. *Obstet Gynecol* 1999; 93:973.
51. Clark SL. Amniotic fluid embolism. *Clin Perinatol* 1986; 13:801.
52. Suidan JS. Amniotic fluid embolism. *Middle East J Anesthesiol* 1989; 10:279.
53. Berg CJ, Callaghan WM, Syverson C, Henderson Z. Pregnancy-related mortality in the United States, 1998 to 2005. *Obstet Gynecol* 2010; 116:1302.
54. Clark SL. Amniotic fluid embolism. *Clin Obstet Gynecol* 2010; 53:322.
55. Kiranpreet Kaur, Mamta Bhardwaj, Prashant Kumar, Suresh Singhal, Tarandeep Singh, Sarla Hooda. Amniotic Fluid Embolism. *J Anaesthesiol Clin Pharmacol*. 2016 Apr-Jun; 32(2): 153-159
56. Society for Maternal-Fetal Medicine (SMFM) with the assistance of Pacheco LD, Saade G, et al. Amniotic fluid embolism: diagnosis and management. *Am J Obstet Gynecol* 2016;215:B16-24.

57. Patient Safety and Quality Committee, Society for Maternal-Fetal Medicine; C. Andrew Combs, MD, PhD; Douglas M. Montgomery, MD; Lorraine E. Toner, MD; Gary A. Dildy, MD. Special Statement: Checklist for initial management of amniotic fluid embolism. Am J Obstet Gynecol 2021.